Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, single-arm, multicenter phase II clinical study of chemotherapy with anlotinib, toripalimab and stereotactic radiotherapy in oligo-metastatic nasopharyngeal carcinoma

Next Previous
Trial Profile

A prospective, single-arm, multicenter phase II clinical study of chemotherapy with anlotinib, toripalimab and stereotactic radiotherapy in oligo-metastatic nasopharyngeal carcinoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Catequentinib (Primary) ; Cisplatin (Primary) ; Gemcitabine (Primary) ; Toripalimab (Primary)
  • Indications Carcinoma; Nasopharyngeal cancer
  • Focus Therapeutic Use

Most Recent Events

  • 08 Jul 2023 New trial record
  • 06 Jun 2023 Preliminary results (n=19; Between January 2022 and January 2023; At the data cutoff date on January 31, 2023) assessing the efficacy and safety of Chemotherapy combined with anlotinib, toripalimab and stereotactic radiotherapy in oligo-metastatic nasopharyngeal carcinoma, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top